Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

Yoshinao Muro, Kazumitsu Sugiura, Masashi Akiyama

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD). Recent studies noted that anti-MDA5 antibody (anti-MDA5ab), ferritin, and IL-18 are useful biomarkers for evaluating the responses to treatment and the status of ILD in anti-MDA5ab-positive DM. In this study, we further studied the importance of anti-MDA5ab levels and of ferritin and IL-18 concentrations in our patients. These biomarkers could be sometimes useful for evaluating ILD status and/or predicting the prognosis in patients with anti-MDA5ab-positive DM with several exceptional cases. A single-point evaluation of anti-MDA5ab levels and of ferritin and IL-18 concentrations has limitations in predicting the prognosis of ILD with DM. We consider that the timing of initial therapy and the anti-MDA5ab isotype, in addition to the patient's age, are also crucial factors for predicting the prognosis.

Original languageEnglish
Pages (from-to)395-398
Number of pages4
JournalClinical Rheumatology
Volume32
Issue number3
DOIs
Publication statusPublished - 01-03-2013

Fingerprint

Interleukin-18
Dermatomyositis
Interstitial Lung Diseases
Ferritins
Anti-Idiotypic Antibodies
Melanoma
Antibodies
Genes
Biomarkers
Autoantibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

@article{6c2c9a764d4240d481bed5109b70ab44,
title = "Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis",
abstract = "Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD). Recent studies noted that anti-MDA5 antibody (anti-MDA5ab), ferritin, and IL-18 are useful biomarkers for evaluating the responses to treatment and the status of ILD in anti-MDA5ab-positive DM. In this study, we further studied the importance of anti-MDA5ab levels and of ferritin and IL-18 concentrations in our patients. These biomarkers could be sometimes useful for evaluating ILD status and/or predicting the prognosis in patients with anti-MDA5ab-positive DM with several exceptional cases. A single-point evaluation of anti-MDA5ab levels and of ferritin and IL-18 concentrations has limitations in predicting the prognosis of ILD with DM. We consider that the timing of initial therapy and the anti-MDA5ab isotype, in addition to the patient's age, are also crucial factors for predicting the prognosis.",
author = "Yoshinao Muro and Kazumitsu Sugiura and Masashi Akiyama",
year = "2013",
month = "3",
day = "1",
doi = "10.1007/s10067-012-2142-x",
language = "English",
volume = "32",
pages = "395--398",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "3",

}

TY - JOUR

T1 - Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

AU - Muro, Yoshinao

AU - Sugiura, Kazumitsu

AU - Akiyama, Masashi

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD). Recent studies noted that anti-MDA5 antibody (anti-MDA5ab), ferritin, and IL-18 are useful biomarkers for evaluating the responses to treatment and the status of ILD in anti-MDA5ab-positive DM. In this study, we further studied the importance of anti-MDA5ab levels and of ferritin and IL-18 concentrations in our patients. These biomarkers could be sometimes useful for evaluating ILD status and/or predicting the prognosis in patients with anti-MDA5ab-positive DM with several exceptional cases. A single-point evaluation of anti-MDA5ab levels and of ferritin and IL-18 concentrations has limitations in predicting the prognosis of ILD with DM. We consider that the timing of initial therapy and the anti-MDA5ab isotype, in addition to the patient's age, are also crucial factors for predicting the prognosis.

AB - Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD). Recent studies noted that anti-MDA5 antibody (anti-MDA5ab), ferritin, and IL-18 are useful biomarkers for evaluating the responses to treatment and the status of ILD in anti-MDA5ab-positive DM. In this study, we further studied the importance of anti-MDA5ab levels and of ferritin and IL-18 concentrations in our patients. These biomarkers could be sometimes useful for evaluating ILD status and/or predicting the prognosis in patients with anti-MDA5ab-positive DM with several exceptional cases. A single-point evaluation of anti-MDA5ab levels and of ferritin and IL-18 concentrations has limitations in predicting the prognosis of ILD with DM. We consider that the timing of initial therapy and the anti-MDA5ab isotype, in addition to the patient's age, are also crucial factors for predicting the prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84876686862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876686862&partnerID=8YFLogxK

U2 - 10.1007/s10067-012-2142-x

DO - 10.1007/s10067-012-2142-x

M3 - Article

VL - 32

SP - 395

EP - 398

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 3

ER -